Observational studyJournal of nephrology2025
Evaluating the impact of Arteriovenous Fistula (AVF) creation on kidney function.
Observational study in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArteriovenous fistula (AVF) creation may slow down the decline of kidney function as shown in few previous studies. Our aim was to evaluate the effect of AVF creation on kidney function and dialysis initiation in predialysis patients.
methodsPredialysis patients with AVFs and estimated glomerular filtration rate (eGFR) recorded on day of AVF creation and at 12 and 6 months pre- and post-AVF creation were identified. Rate of decline (RoD) of eGFR and Kidney Failure Risk Equation Score (KFRE) was recorded pre- and post-AVF creation at 6 and 12 months. Patients with non-functioning AVFs were identified and RoD was compared to functioning AVFs. Patients undergoing haemodialysis pre- and post-AVF creation were identified.
resultsOverall, 368 patients and 435 patients were identified for the 12-month and 6-month group, respectively. Rate of decline of eGFR 6 months pre-AVF creation was -0.33 ml/min/1.73m2/month which slowed down to -0.23 ml/min/1.73m2/month in the 6 months post-AVF creation. Rate of decline of eGFR 12 months pre-AVF creation was -0.37 ml/min/1.73m2/month and slowed down to -0.19 ml/min/1.73m2/month in the 12 months post-AVF creation. KFRE increased at a slower rate at 6 and 12 months post-AVF. One hundred sixty-two patients had functioning AVFs while 29 patients had non-functioning AVFs at 6 months post-AVF creation. Rate of decline of eGFR in patients with functioning AVF was -0.22 ml/min/1.73m2/month compared to -0.32 ml/min/1.73m2/month in patients with non-functioning AVF; 246 patients (62.3%) were commenced on haemodialysis in the 12 months pre- and post- AVF creation.
conclusionAVF creation was associated with a slower rate of decline of kidney function. However, this is unlikely to delay the commencement of haemodialysis in predialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.